To further support our findings, exome sequencing datasets showed that the GNA13 gene was amplified in 4% (21/492) of primary prostate adenocarcinoma samples in The Cancer Genome Atlas (TCGA) and in 28% (123/444) of metastatic castration-resistant prostate cancers (CRPCs) in the SU2C/PCF datasets [Supplementary Figure S2A] [20,21,37]. Here, GNA13 is linked to prostate adenocarcinoma.